登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Science，3月6日，Can China's COVID-19 strategy work elsewhere?》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-06

  • Can China's COVID-19 strategy work elsewhere?

    Kai Kupferschmidt, Jon Cohen

    See all authors and affiliations

    Science 06 Mar 2020:

    Vol. 367, Issue 6482, pp. 1061-1062

    DOI: 10.1126/science.367.6482.1061

    Chinese hospitals overflowing with COVID-19 patients a few weeks ago now have empty beds. Trials of experimental drugs can't find enough eligible patients. And the number of new cases reported each day in China is dropping precipitously.

  • 原文来源：https://science.sciencemag.org/content/367/6482/1061
40浏览量
原文链接
相关报告

  • 《ChinaXiv，3月6日，Effective Treatment of Severe COVID-19 Patients with Tocilizumab》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-07
    • Effective Treatment of Severe COVID-19 Patients with Tocilizumab 提交时间： 2020-03-05 作者： Xu, Xiaoling 1 ; Han, Mingfeng 2 ; Li, Tiantian 1 ; Sun, Wei 2 ; Wang, Dongsheng 1 ; Fu, Binqing 3,4 ; Zhou, Yonggang 3,4 ; Zheng, Xiaohu 3,4 ; Yang, Yun 1 ; Li, Xiuyong 2 ; Zhang, Xiaohua 2 ; Pan, Aijun 1 ; Wei, Haiming 3,4 ; 内容摘要 Background: In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China, which spread rapidly and has become a world-wide public health challenge. We aimed to assess the efficacy of tocilizumab in severe patients with Corona Virus Disease-19 (COVID-19) and seek a new therapeutic strategy. Methods: The patients diagnosed as severe or critical COVID-19 in The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) and Anhui Fuyang Second People’s Hospital were given tocilizumab in addition to routine therapy between February 5 and February 14, 2020. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    59浏览量
    原文链接

  • 《MedRxiv，3月6日，Age-dependent risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-03-07
    • Age-dependent risks of Incidence and Mortality of COVID-19 in Hubei Province and Other Parts of China Hongdou Li, Shuang Wang, Fan Zhong, Wuyin Bao, Yipeng Li, Lei Liu, Hongyan Wang, Yungang He doi: https://doi.org/10.1101/2020.02.25.20027672 Abstract New coronavirus SARS-CoV-2 poses a big challenge for global public health in early 2020. Coronavirus Disease 2019 (COVID-19) caused by the virus rapidly spreads all over the world and takes thousands of lives in just two months. It is critical to refine the incidence and mortality risks of COVID-19 for the effective management of the general public and patients in the outbreak. In this report, we investigate the incidence and mortality risks of the infection by analyzing the age composition of 5319 infected patients, 76 fatal cases, and 1,144,648 individuals of the general public in China. Our result shows a relatively low incidence risk for young people but a very high mortality risk for seniors. Notably, mortality risk could be as high as 0.48 for people older than 80 years. Furthermore, our study suggests that a good medical service can effectively reduce the mortality rate of the viral infection to 1% or less. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    105浏览量
    原文链接